GlassScriptPhysician profile
Christopher J Morgan
NPI 1245550268
$811.85
in general payments reported to CMS, 2019-2025
15 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.15 · 2022: $48.61 · 2023: $75.55 · 2024: $253 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $193.11 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $116.12 | 2025 | Wegovy |
| Corcept Therapeutics | $72.46 | 2025 | Korlym |
| Boston Scientific Corporation | $63.64 | 2024 | Intracept |
| Medtronic, INC. | $62.30 | 2025 | Inceptiv, Minimed 780g |
| Genzyme Corporation | $60.62 | 2023 | |
| Sequel Med Tech, LLC | $54.49 | 2025 | Twiist |
| Abbott Laboratories | $48.61 | 2022 | |
| Tandem Diabetes Care, INC. | $43.58 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $25.36 | 2025 | Isturisa |
| Endo Pharmaceuticals INC. | $18.09 | 2024 | Aveed |
| Galderma Laboratories, L.P. | $18.06 | 2024 | |
| Lilly USA, LLC | $13.80 | 2025 | Mounjaro |
| Vistapharm, INC. | $11.16 | 2021 | |
| Beta Bionics, INC. | $10.45 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.